Skip to main content

Table 6 Summary of outcomes resulting from introducing non-invasive liver fibrosis tests in primary care (per 1000 NAFLD patients over 1 years)

From: Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease

  Scenario 1
Standard Care
Scenario 2
FIB 4 +/− ELF
Scenario 3
FIB 4 +/− TE
Scenario 4
ELF
Scenario 5
TE
Total Referrals avoided (vs. SOC) 245 234 198 150
Cases F3/F4 detected 26.3 56.1 57.1 60.0 62.2
Cases Cirrhosis detected 5.3 11.0 11.2 11.8 12.3
Cases Cirrhosis missed 11.3 5.5 5.3 4.7 4.2
Cost saving (vs. SOC) - £169,408 - £151,816 - £101,268 - £26,889
Cost per ≥ F3 detected £25,543 £8932 £9083 £9487 £10,351